Considering the background of HCC, the impact of panitumumab on its receptor of target and downstream major signaling activators, AKT and ERK, involved in thyroid tumorigenesis, was analyzed in an HCC cell line model with a NHG. This evidence concerns the gene AKT1 and thyroid gland disorder.